3rd Global Meeting on Implementing New and Under-utilized Vaccines, 16-18 June 2009
Background
The Global Meeting in Implementing New and Under-utilized Vaccines (NUVI) is organized by WHO and partners on an annual basis. It serves as a forum for individuals working at global, regional and country levels, both in the private and public sectors, to discuss issues pertaining to the introduction of new and under-utilized vaccines.
The Third Annual Global NUVI meeting was organized by WHO/HQ and held in Montreux, Switzerland from 16-18 June 2009 with over 130 participants including representatives from WHO, UNICEF (HQ, Regional and Country Offices), Ministries of Health, National Advisory Committees, Academia, NGOs, industry, and Partner Agencies including AMP, The Bill and Melinda Gates Foundation, CDC, GAVI, Hib Initiative, JSI, and PATH.
The main objectives of this year's meeting were the following:
- Discuss programmatic achievements including progress with implementation of Hib, pneumococcal, rotavirus and other vaccines, and prioritize activities for the next 12 months.
- Review key issues in new and under-utilized vaccine introduction among immunization partners, regions and countries.
- Discuss the financing of health care and new vaccines in times of crisis.
- Provide an update of the A(H1N1) influenza situation and preparedness.
Priorities to be undertaken by the different partner institutions in the coming year were identified, the main ones being to continue to support fully informed decision-making on the introduction of new vaccines, balancing new vaccines introduction with routine immunization and delivery systems strengthening, and accelerating strategies to mobilize resources to cover the costs of introducing newly available vaccines
Further information
- Context
- Introductory session
- Workgroup 1. Use of local surveillance data to assess impact of new vaccines for advocacy of sustainable financing
- Workgroup 2. Coordination between National Regulatory Authorities and National Immunization Technical Advisory Groups and/or Immunization Managers
- Workgroup 3. Looking at visual cues and choosing preferred vaccine presentations
- Workgroup 4. Lessons learned from the field: Health risk and crisis communications for real or perceived risks due to vaccination
- Workgroup 5. Cold chain and logistics systems for preparedness for the introduction of PCV, Rotavirus, HPV and other new vaccines
- Workgroup 6. Pneumococcal conjugate vaccine cost-effectiveness assessments
- Workgroup 7. Opportunities and barriers in new vaccine introduction decisions in GAVI-eligible countries, including large countries
- Workgroup 8. Training of health staff and review of the Global Immunization Training Framework
- Workgroup 9. Integrated approaches to pneumonia and diarrhoea management control
-
Full document
pdf, 181kb